title: Concurrent radiotherapy and weekly chemotherapy of 5-fluorouracil and platinum agents for postoperative locoregional recurrence of oesophageal squamous cell carcinoma.
abstract: The most optimal management for postoperative locoregional recurrence of oesophageal squamous cell carcinoma is still controversial. Several studies have reported the feasibility and efficacy of concurrent chemoradiotherapy (CCRT), mostly with three-weekly or four-weekly schedule of chemotherapy. However, treatment compliance was not quite satisfactory, probably due to treatment-related toxicities. Since CCRT with weekly chemotherapy regimens have demonstrated a favorable toxicity profile as well as promising survival in certain types of cancer, we aimed to evaluate the efficacy and toxicity of radiotherapy concurrently with weekly chemotherapy with 5-fluorouracil (5-FU) and platinum agents for patients with postoperative locoregional recurrence of oesophageal squamous cell carcinoma in our center. Twenty-seven consecutive patients who were diagnosed with postoperative locoregional recurrence of oesophageal squamous cell carcinoma and received CCRT with weekly chemotherapy of 5-FU and platinum agents were retrospectively analyzed. Our data showed that the present protocol of radiotherapy combined concurrently with weekly chemotherapy of 5-FU and platinum agents was a safe and effective salvage treatment for postoperative locoregional recurrence of oesophageal squamous cell carcinoma.
authors: 1] State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, P.R. China [2] Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, P.R. China [3] Guangdong Esophogeal Cancer Research Institute, Guangzhou, Guangdong, P.R. China.
authors: Wen-Wen
authors: WW
authors: Zhang
authors: 1] State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, P.R. China [2] Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, P.R. China [3] Guangdong Esophogeal Cancer Research Institute, Guangzhou, Guangdong, P.R. China.
authors: Yu-Jia
authors: YJ
authors: Zhu
authors: 1] State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, P.R. China [2] Department of Thoracic Surgery, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, P.R. China [3] Guangdong Esophogeal Cancer Research Institute, Guangzhou, Guangdong, P.R. China.
authors: Han
authors: H
authors: Yang
authors: 1] State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, P.R. China [2] Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, P.R. China [3] Guangdong Esophogeal Cancer Research Institute, Guangzhou, Guangdong, P.R. China.
authors: Qiao-Xuan
authors: QX
authors: Wang
authors: 1] State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, P.R. China [2] Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, P.R. China [3] Guangdong Esophogeal Cancer Research Institute, Guangzhou, Guangdong, P.R. China.
authors: Xiao-Hui
authors: XH
authors: Wang
authors: 1] State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, P.R. China [2] Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, P.R. China [3] Guangdong Esophogeal Cancer Research Institute, Guangzhou, Guangdong, P.R. China.
authors: Wei-Wei
authors: WW
authors: Xiao
authors: 1] State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, P.R. China [2] Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, P.R. China [3] Guangdong Esophogeal Cancer Research Institute, Guangzhou, Guangdong, P.R. China.
authors: Qiao-Qiao
authors: QQ
authors: Li
authors: 1] State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, P.R. China [2] Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, P.R. China [3] Guangdong Esophogeal Cancer Research Institute, Guangzhou, Guangdong, P.R. China.
authors: Meng-Zhong
authors: MZ
authors: Liu
authors: 1] State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, P.R. China [2] Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, P.R. China [3] Guangdong Esophogeal Cancer Research Institute, Guangzhou, Guangdong, P.R. China.
authors: Yong-Hong
authors: YH
authors: Hu
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D059248:Chemoradiotherapy; D004334:Drug Administration Schedule; D004938:Esophageal Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D000077277:Esophageal Squamous Cell Carcinoma; D005260:Female; D005472:Fluorouracil / Q000009:adverse effects / Q000627:therapeutic use*; D006402:Hematologic Diseases / Q000209:etiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D009944:Organoplatinum Compounds / Q000009:adverse effects / Q000627:therapeutic use; D049268:Positron-Emission Tomography; D012189:Retrospective Studies; D015996:Survival Rate; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; C053989:nedaplatin; D005472:Fluorouracil
references: Ann Thorac Surg. 1994 Mar;57(3):677-81
references: 8147640
references: Gut. 1995 Aug;37(2):174-6
references: 7557562
references: Br J Surg. 1996 Jan;83(1):107-11
references: 8653330
references: World J Surg. 1997 Mar-Apr;21(3):275-81
references: 9015170
references: Jpn J Clin Oncol. 2004 Nov;34(11):647-53
references: 15613553
references: Cancer. 2013 Mar 1;119(5):939-45
references: 23165781
references: Dis Esophagus. 2014 Jan;27(1):72-8
references: 23551708
references: Radiat Oncol. 2013;8:241
references: 24139225
references: Radiat Oncol. 2014;9:28
references: 24438695
references: Radiat Oncol. 2014;9:55
references: 24533532
references: J Clin Oncol. 2005 Apr 1;23(10):2310-7
references: 15800321
references: BMC Cancer. 2006;6:50
references: 16515704
references: Ann Surg Oncol. 2008 Sep;15(9):2451-7
references: 18592318
references: Dis Esophagus. 2009;22(1):1-8
references: 19196264
references: Gynecol Oncol. 2009 Aug;114(2):215-8
references: 19446318
references: Ann Oncol. 2009 Sep;20(9):1522-8
references: 19465425
references: Lancet. 2009 Oct 17;374(9698):1331-8
references: 19767092
references: Int J Radiat Oncol Biol Phys. 2010 Nov 1;78(3):710-4
references: 20172661
references: Br J Surg. 1946 Jul;34:18-31
references: 20994128
references: Eur J Gynaecol Oncol. 2010;31(5):517-21
references: 21061792
references: Dis Esophagus. 2011 Apr;24(3):166-71
references: 20946135
references: Strahlenther Onkol. 2012 Feb;188(2):136-42
references: 22218502
references: Radiat Oncol. 2012;7:93
references: 22713587
references: BMC Cancer. 2012;12:542
references: 23171077
references: Br J Cancer. 2007 Feb 12;96(3):432-8
references: 17245338
references: Cancer Chemother Pharmacol. 2008 Feb;61(2):243-50
references: 17393164
references: Jpn J Clin Oncol. 2007 Dec;37(12):918-23
references: 18211982
references: Oncol Rep. 2008 Jun;19(6):1551-6
references: 18497964
references: J Am Coll Surg. 2000 Aug;191(2):143-8
references: 10945357
references: Radiother Oncol. 2001 Nov;61(2):165-8
references: 11690682
references: Hepatogastroenterology. 2003 Jan-Feb;50(49):115-20
references: 12630005
references: Jpn J Thorac Cardiovasc Surg. 2003 Nov;51(11):599-608
references: 14650590
references: J Am Coll Surg. 2004 Feb;198(2):205-11
references: 14759776
references: Ann Surg. 1987 Feb;205(2):189-94
references: 3813689